CA3014728A1 - Methods of treating diseases characterised by vasoconstriction - Google Patents

Methods of treating diseases characterised by vasoconstriction Download PDF

Info

Publication number
CA3014728A1
CA3014728A1 CA3014728A CA3014728A CA3014728A1 CA 3014728 A1 CA3014728 A1 CA 3014728A1 CA 3014728 A CA3014728 A CA 3014728A CA 3014728 A CA3014728 A CA 3014728A CA 3014728 A1 CA3014728 A1 CA 3014728A1
Authority
CA
Canada
Prior art keywords
benzo
carboxamide
piperidine
vasoconstriction
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3014728A
Other languages
English (en)
French (fr)
Inventor
Per-Johan Jakobsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gesynta Pharma AB
Original Assignee
Gesynta Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gesynta Pharma AB filed Critical Gesynta Pharma AB
Publication of CA3014728A1 publication Critical patent/CA3014728A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3014728A 2016-02-25 2017-02-24 Methods of treating diseases characterised by vasoconstriction Pending CA3014728A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1603311.0 2016-02-25
GBGB1603311.0A GB201603311D0 (en) 2016-02-25 2016-02-25 New uses and methods
PCT/GB2017/050498 WO2017144909A1 (en) 2016-02-25 2017-02-24 Methods of treating diseases characterised by vasoconstriction

Publications (1)

Publication Number Publication Date
CA3014728A1 true CA3014728A1 (en) 2017-08-31

Family

ID=55806947

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3014728A Pending CA3014728A1 (en) 2016-02-25 2017-02-24 Methods of treating diseases characterised by vasoconstriction

Country Status (9)

Country Link
US (2) US20190038603A1 (enExample)
EP (1) EP3419620A1 (enExample)
JP (1) JP2019510079A (enExample)
CN (1) CN109069487A (enExample)
AU (1) AU2017222406B2 (enExample)
CA (1) CA3014728A1 (enExample)
GB (1) GB201603311D0 (enExample)
RU (1) RU2018133818A (enExample)
WO (1) WO2017144909A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111417394B (zh) 2017-10-19 2023-11-07 帝人制药株式会社 苯并咪唑衍生物及其用途
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
CA3156828A1 (en) 2019-10-03 2021-04-08 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
WO2021096314A1 (ko) * 2019-11-15 2021-05-20 가천대학교 산학협력단 신규한 벤즈이미다졸 유도체 및 이의 용도
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
TW202409037A (zh) * 2022-07-06 2024-03-01 日商Ａｓｋａ製藥股份有限公司 嘧啶衍生物
GB202212749D0 (en) 2022-09-01 2022-10-19 Gesynta Pharma Ab New uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2207547A4 (en) * 2007-10-05 2010-11-17 Amira Pharmaceuticals Inc PROTEIN INHIBITORS THAT ACTIVATE 5-LIPOXYGENASE
UY32470A (es) * 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2011023812A1 (en) * 2009-08-27 2011-03-03 Novasaid Ab Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
US8759537B2 (en) * 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
EP2495244A1 (en) * 2011-03-02 2012-09-05 NovaSaid AB Piperidinyl benzoimidazole derivatives as mPGEs-1 inhibitors
ES2561105T3 (es) * 2011-08-18 2016-02-24 Nippon Shinyaku Co., Ltd. Derivado heterocíclico como inhibidor de prostaglandina E sintasa microsómica (mPGES)
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
KR20160134865A (ko) * 2014-04-14 2016-11-23 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 아미드 유도체 및 이의 약제학적으로 허용되는 염, 이의 제조방법 및 이의 의학적 적용

Also Published As

Publication number Publication date
GB201603311D0 (en) 2016-04-13
AU2017222406B2 (en) 2022-06-02
JP2019510079A (ja) 2019-04-11
AU2017222406A1 (en) 2018-08-30
EP3419620A1 (en) 2019-01-02
US20220218670A1 (en) 2022-07-14
RU2018133818A (ru) 2020-03-25
WO2017144909A1 (en) 2017-08-31
CN109069487A (zh) 2018-12-21
US20190038603A1 (en) 2019-02-07
RU2018133818A3 (enExample) 2020-05-27

Similar Documents

Publication Publication Date Title
US20220218670A1 (en) Methods of treating diseases characterised by vasoconstriction
JP6941147B2 (ja) アリール受容体モジュレーターならびにその作製および使用方法
DE69801680T2 (de) Zusammensetzungen welche aldosereductasehemmer und glycogen phosphorylase hemmer enthalten
EP1954683B1 (en) 2-(phenyl or heterocyclyl)-1h-phenanthro(9,10-d)imidazoles as mpges-1 inhibitors
DE60319711T2 (de) Acylamino-substituierte heteroaromatische verbindungen und ihre verwendung als arzneimittel
JP6212644B2 (ja) フェノキシエチル環状アミン誘導体およびｅｐ４受容体モジュレーターとしてのその活性
SK8732003A3 (en) Isoindolin-1-one glucokinase activators
EA005028B1 (ru) Пиримидинкарбоксамиды, используемые в качестве ингибиторов изозимов pde4
KR20080012304A (ko) 피라졸 화합물 및 이들 피라졸 화합물을 포함하여이루어지는 당뇨병 치료약
JP2001506231A (ja) ヘテロ環式チオエステルおよびケトン
FR2962649A1 (fr) Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
JP2017141270A (ja) １−（５，６−ジクロロ−１ｈ−ベンゾ［ｄ］イミダゾール−２−イル）−１ｈ−ピラゾール−４−カルボン酸のメグルミン塩製剤
US20220226508A1 (en) Methods and compositions for treating epilepsy
US20110212973A1 (en) Carbamate compound or salt thereof
US7183285B2 (en) Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
RS54737B1 (sr) Derivati benzazola kao veznici h4 receptora histamina
JP2005525309A (ja) 医薬品としての使用のためのＭＴＰインヒビター又はａｐｏＢ分泌インヒビターとフィブレートの組み合わせ
JP2007535558A (ja) キナーゼおよび／またはｈｍｇ−ｃｏａレダクターゼを阻害するための組成物および処置
US7163945B2 (en) Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
WO2024050434A1 (en) ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
EP2917204B1 (fr) Derives de 1h-indole-3-carboxamide et leurs utilisation comme antagonistes du p2y12
CN1141590A (zh) 用于预防和治疗凝血噁烷a2介导的疾病的药物
US20050272770A1 (en) Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US6426356B1 (en) Imidazoethyl thiophenes
US20260069553A1 (en) TAPINAROF AND ANALOGS THEREOF FOR USE IN TREATING AhR MEDIATED DISEASES

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220216